#pharmaceutical

बायोफार्मा कंपनियां MFN प्राइसिंग नियमों के प्रति अपने एक्सपोजर को कम करने के लिए अंतर्राष्ट्रीय लाइसेंसिंग समझौतों को पुनर्गठित कर रही हैं, जो अमेरिकी दवा की कीमतों को अन्य देशों में दी गई सबसे कम कीमतों से जोड़ते हैं।

Ugur Sahin and Ozlem Tureci will exit BioNTech by year-end to start a company focused on next-generation mRNA innovations.

Pharmaceutical giant GSK has agreed to buy 35Pharma, a biotech focused on pulmonary hypertension, for $950 million. The deal expands GSK's respiratory and cardiovascular portfolio with a pipeline targeting a disease that currently has limited treatment options.

Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.